Stay Up to Date! Like us on Facebook  and Twitter  for the latest news and announcements    

Primary Mitochondrial Myopathy Clinical Trial Update

Join Us

Friday, March 08 2019 12:00pm EST

Find your Timezone

Use this link to join the webinar:


Or iPhone one-tap :

    US: +16465588656,,863044848#  or +16699006833,,863044848# 

Or Telephone:

    Dial (for higher quality, dial a number based on your current location):

        US: +1 646 558 8656  or +1 669 900 6833

Webinar ID: 863 044 848

    International numbers available:


All are welcome!

For help participating if you are deaf or hearing-impared, click here

View all podcasts in iTunes

Please join Mito Action and UMDF on FRIDAY MARCH 8th at 12 pm Eastern time (9 am PST) for a special presentation by Stealth BioTherapeutics’ CEO, Reenie McCarthy, and Chief Clinical Development Officer, Jim Carr, as well as other guest speakers. 

Join us for this free webinar to learn more about:

  • MMPOWER UPDATE: An update on MMPOWER-3, a Phase 3 clinical trial in primary mitochondrial myopathy scheduled to close enrollment over the next couple of months.
  • PATIENTS AS ADVOCATES FOR CHANGE: Your voice matters! Help shape the future of mitochondrial therapeutics through participation in clinical development initiatives.
  • DISEASE BURDEN: Insights gained from reviewing costs associated with medical management of mitochondrial disease – an important topic for insurers and regulators to understand the severity of the disease burden.
  • GET INVOLVED! Learn how to participate in the UMDF Patient Focused Drug Development Meeting scheduled on March 29thto inform the FDA about your experience living with mitochondrial disease.


All are welcome and encouraged to listen to this live presentation. An opportunity to submit questions online will be provided during the live webinar. 



 Primary Mitochondrial Myopathy Clinical Trial Update, the Importance of the Voice of the Patient and a Review of the Healthcare Costs Associated with the Management of Mitochondrial Disease. 

No votes yet